Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases
H. Mouas(Hôpital Necker-Enfants Malades), Irja Lutsar(University of Tartu), O. Fain(Sorbonne Université), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Olivier Lortholary(Hôpital Necker-Enfants Malades), B. Dupont(Délégation Paris 5), François-Xavier Lescure(Inserm)
Cited by 125
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k